You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》美銀證券下調百濟神州(06160.HK)目標價至128.02元 評級「中性」
美銀證券發表報告指,百濟神州(06160.HK)的PD-1抑制劑新藥Tislelizumab獲得歐盟批准,用於曾經治療的晚期或轉移性食道鱗狀細胞癌(ESCC),美國食品藥物管理局(FDA)亦受理該藥物的生物製劑申請,目標明年下半年作出審核決定。 公司在2021年1月,就該藥物在美國、歐盟及日本的商業化,與瑞士諾華(Novartis)達成合作,不過兩間公司宣布合作終止,百濟神州將擁有該藥物完整的全球開發權利。 美銀認為,以策略角度而言,對公司取得Tislelizumab的完整商業權感到樂觀,但關注該藥物在已發展地區商業化進度及能力,特別是美國及歐盟,因為其他藥物Keytruda及Opdivo具有主導地位。該行提高百濟神州推廣開支的預測,目標價由135.34元下調至128.02元,維持「中性」評級。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account